| |
Click on one of the links below to consult the corresponding paper [in french]
:
|
June 6th 2007 |
 La Gazette du Laboratoire
Extract : (...) (...)
|
Jan. 2006 |
Industrie Pharma Magazine
Extract : (...) (...)
|
Jan. 2005 |
Le Moniteur des Pharmacies
Extract : (...) (...)
|
March-April 2004 |
La
Lettre de la Technopole
Extract : (...) (...)
|
June 6th 2002 |
La
Gazette du Laboratoire
Extract : (...) (...)
|
2002 |
Le
Guide National des Praticiens Hospitaliers
Extrait : (...) (...)
|
|
Feb.-Mar., 2002 |
La
Lettre de la Technopole
Extract : (...) (...)
|
|
Jan. 24th, 2002 |
L'usine
nouvelle
Extract : (...) (...)
|
|
June 28th, 2001 |
L'usine
nouvelle
Extract : (...) (...)
|
|
April 17th, 2001 |
Le
Moniteur des Pharmacies
Extract : (...) an exhaustif range of thermal analyses of active
substances, study of polymorphism of active substances and analyses of interactions
between active substance and other compounds used in the formulation of drugs.
The innovative nature of these analyses resides in the use of a computer program
for modelling these interactions, thus aiding the choice of excipient (different
compounds). (...)
|
|
April 5th, 2001 |
La
Gazette du Laboratoire
Extract : (...) Our project is unique in France. At present no other
companies offer such services in this field. (...) Calytherm will develop a computer
program to model interactions between the active substance and different compounds.
By modelling in this way, the manufacturer can choose the excipient best adapted
to the active substance. (...)
|
|
Jan. 16th, 2001 |
La
Lettre M
Extract : Calytherm offers services For The Pharmaceutical Industry.
The company is developing a computer program to model interactions between the
active substance and its excipient. (...)
|
|
Jan.-Feb. 2001 |
La
Lettre de la Technopole
Extract : The society Calytherm is one of the ten prize-winners
of the Fondation Aventis -Institut de France. (...) Calytherm which is managed
by Fabienne Lacoulonche specialises in pharmaceutical quality control. (...)
|
|
Jan. 10th, 2001 |
Les
Tremplins de la Fondation Aventis - Institut de France
Extract : 250 million dollars : these are the dramatic financial
consequences for a big American pharmaceutical company. (...) A new crystalline
form of the active substance appeared.(...) In order to reduce the risk of such
crystalline modifications, there is only one solution : (to) predict everything.
(...)This is exactly what Calytherm offers to the pharmaceutical industry. (...)
|
|
Nov. 15th, 2000 |
Le
Midi Libre
Extract : The big pharmaceutical industries, from Pierre Fabre to
Merck, are looking for service companies capable of thermal and spectral analyses
to predict the effects of temperature and dissolution on therapeutic activity.
(...)
|
|
Oct. 12th, 2000 |
L'Hérault
Judiciaire et Commercial
Extract : Calytherm a new company specialising in pharmaceutical
quality control, a growing market sector in the pharmaceutical industry (...)
|
|
Mar. 28th, 2000 |
L'Hérault
du Jour
Extract : Researchers can found their own companies without leaving
the university by using the mechanisms established by the recent " innovation
Law " of November 12 th 1999.(…) It is a potential market : the pharmaceutical
companies can no longer run the risk of ignoring drug polymorphism.(...)
|
|
Mar. 7th, 2000 |
France-Zoom
Extract : Etant donnée l'exigence actuelle des autorités
réglementaires pour l'autorisation de mise sur le marché (AMM) du
médicament, les laboratoires pharmaceutiques sont obligés de réaliser
des études plus approfondies du polymorphisme des médicaments. (...)
|
|
Sept.-Oct., 1999 |
La
Lettre de la Technopole
Extract : Fabienne Lacoulonche, docteur de l'Université Montpellier
I en sciences pharmaceutiques, décide de monter un projet d'entreprise
inspiré de sa spécialité scientifique : l'étude du
polymorphisme du principe actif des médicaments. Derrière cette
expression ésotérique se cache un enjeu important. (...)
|
|
Oct. 19th, 1999 |
Le
Midi Libre
Extract : "Quand en France, l'étude du polymorphisme
sera obligatoire, continue-t-elle, les groupes pharmaceutiques feront appel à
des entreprises prestataires." (...)
|
